Compound Name;Alternative name in publication;EC50 [uM];Result ;CC50 [uM];Virus Strain;Cell type;Reported activity in URL;Reference;Smiles code;;;
ribavirin;;109,5;;>400;clinical nCoV;Vero E6;;https://www.ncbi.nlm.nih.gov/pubmed/32020029;NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O;;;
nafamostat;Buipel;22,5;;>100;clinical nCoV;Vero E6;serine protease inhibitor;https://www.ncbi.nlm.nih.gov/pubmed/32020029;NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC2=C(C=C1)C=C(C=C2)C(N)=N;;;
penciclovir;;95,96;;>400;clinical nCoV;Vero E6;;https://www.ncbi.nlm.nih.gov/pubmed/32020029;NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2;;;
nitazoxanide;;2,12;;35,53;clinical nCoV;Vero E6;;https://www.ncbi.nlm.nih.gov/pubmed/32020029;CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O;;;
chloroquine;;1,13;;>100;clinical nCoV;Vero E6;;https://www.ncbi.nlm.nih.gov/pubmed/32020029;CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12;;;
remdesivir ;GS5734;0,77;;>100;clinical nCoV;Vero E6;;https://www.ncbi.nlm.nih.gov/pubmed/32020029;CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1;;;
favipiravir;T-705;61,88;;>400;clinical nCoV;Vero E6;;https://www.ncbi.nlm.nih.gov/pubmed/32020029;;;;
camostat mesilate/camostat;FOY-305/Foipan;;active;;isolate Munich 929 ;Calu-3;TMPRSS2 protase inhib.;https://www.ncbi.nlm.nih.gov/pubmed/32360480;;;;
hydroxychloroquine;QuensylTM, PlaquenilTM, HydroquinTM, DolquineTM, QuinoricT;0,72;;;;Vero;elevates the pH in endosomes;Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237.;;;;
chloroquine;Resochi;5,47;;;;Vero;inhibits terminal phosphorylation of ACE2;Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237.;;;;
Apilimod;;0,023;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;Phosphoinositide kinase;https://doi.org/10.1101/2020.04.16.044016 ;;;;
Z LVG- CHN2;;0,19;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;Cystein protease;https://doi.org/10.1101/2020.04.16.044016 ;;;;
MDL 28170;;0,22;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;Cystein protease;https://doi.org/10.1101/2020.04.16.044016 ;;;;
VBY-825;;~0.3;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;Cystein protease;https://doi.org/10.1101/2020.04.16.044016 ;;;;
ONO 5334;;~0.5;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;Cystein protease;https://doi.org/10.1101/2020.04.16.044016 ;;;;
remdesivir ;;0,62;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;antiviral;https://doi.org/10.1101/2020.04.16.044016 ;;;;
AMG-2674;;~0.95;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;ion channel;https://doi.org/10.1101/2020.04.16.044016 ;;;;
HanfangchiA;;~1.1;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;ion channel;https://doi.org/10.1101/2020.04.16.044016 ;;;;
YH-1238;;~0.95;;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;proton pump;https://doi.org/10.1101/2020.04.16.044016 ;;;;
MLN-3897;;0,14;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;G prot. coupled receptor;https://doi.org/10.1101/2020.04.16.044016 ;;;;
SDZ-62-434;;0,75;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;G prot. coupled receptor;https://doi.org/10.1101/2020.04.16.044016 ;;;;
SB-616234-A;;~1.2;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;G prot. coupled receptor;https://doi.org/10.1101/2020.04.16.044016 ;;;;
8(3-chlorostyryl)caffeine;;1,6;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;G prot. coupled receptor;https://doi.org/10.1101/2020.04.16.044016 ;;;;
N-tert-Butylisoquine;;~1.2;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;Chloroquine derivative;https://doi.org/10.1101/2020.04.16.044016 ;CC(C)(C)NCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O;;;
SL-11128;;~0.25;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;unspecified;https://doi.org/10.1101/2020.04.16.044016 ;;;;
Elopiprazole;;~1.1;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;unspecified;https://doi.org/10.1101/2020.04.16.044016 ;;;;
Astemizole;;~1.1;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;unspecified;https://doi.org/10.1101/2020.04.16.044016 ;;;;
KW8232;;~1.2;not reported;;SARS-CoV-2  USA-WA1/2020 patient derived;Vero E6;unspecified;https://doi.org/10.1101/2020.04.16.044016 ;;;;
1-Deoxynojirimycin;;not reported;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;α-glucosidase inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
4E1Rcat;;not reported;inactive/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
4E2RCat;;not reported;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;eIF4E/G PPI inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
4EGI-1;;not reported;inactive/inconclusive;;;Vero E6;Translation Initiation Targets;https://doi.org/10.1038/s41586-020-2286-9;;;;
4EGI-1;;not reported;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Translation Initiation Targets;https://doi.org/10.1038/s41586-020-2286-9;;;;
ABBV-744;;not reported;inactive;;;Vero E6;BRD inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
ABBV-744;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
AC-55541;;;;;;Vero E6;PAR agonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
AC-55541;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Apicidin;;;inactive;;;Vero E6;HDAC inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Apicidin;;;Inconclusive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
AZ3451;;;inactive;;wt;Vero E6;PAR2 negative allosteric modulator ;https://doi.org/10.1038/s41586-020-2286-9;;;;
AZ3451;;;Active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;mitochondrial ribosomes;https://doi.org/10.1038/s41586-020-2286-9;;;;
Azithromycin;;;weak/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Bafilomycin A1;;;;;;Vero E6;ATPase inhibitor ;https://doi.org/10.1038/s41586-020-2286-9;;;;
Bafilomycin A1;;;active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
BD1008;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma1 agonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
Camostat;;;inactive;;;Vero E6;Serine protease 1 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Camostat;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Captopril;;;inactive;;;Vero E6;ACE inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Captopril;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Carbapentane;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma1 agonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
;;;;;;;Sigma2 binder;;;;;
CB5083;;;agonist;;;Vero E6;p97 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Chloramphenicol;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;mitochondrial ribosome inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Clemastine;;;active;;;Vero E6;Sigma 1/2 binder;https://doi.org/10.1038/s41586-020-2286-9;;;;
Clemastine;;;Inconclusive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma 1/2 binder;https://doi.org/10.1038/s41586-020-2286-9;;;;
Cloperastine;;;active;;;Vero E6;Sigma 1/2 binder;https://doi.org/10.1038/s41586-020-2286-9;;;;
Cloperastine;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma 1/2 binder;https://doi.org/10.1038/s41586-020-2286-9;;;;
Compound 10;;;inactive/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Compound 10;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;PI4K-IIIß inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Compound 2;;;inactive;;;Vero E6;Cyclophilin inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Compound 2;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
CPI-0610;;;inactive;;;Vero E6;BRD inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
CPI-0610;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Daunorubicin;;;agonist;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Daunorubicin;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Topoisomerase inhibitor ;https://doi.org/10.1038/s41586-020-2286-9;;;;
DBeQ;;;inconclusive;;;Vero E6;p97 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
dBET6;;;active;;;Vero E6;Degrades BRD proteins;https://doi.org/10.1038/s41586-020-2286-9;;;;
dBET6;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Dextromethorphan;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Dextromethorphan;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma 1 binder;https://doi.org/10.1038/s41586-020-2286-9;;;;
E-52862;;;inactive;;;Vero E6;Sigma 1 antagonist ;https://doi.org/10.1038/s41586-020-2286-9;;;;
E-52862;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
H-89;;;;;;Vero E6;Protein kinase A inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
H-89;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Haloperidol;;;active;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Haloperidol;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma 1 antagonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
;;;;;;;Sigma 2 agonist;;;;;
Hydroxychloroquine;;;active;;;Vero E6;Sigma 1/2 binder;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ifenprodil;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma1 agonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
;;;;;;;Sigma2 binder;;;;;
Indomethacin;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Indomethacin;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Prostaglandin E2 synthase inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
JQ1;;;Partial active;;;Vero E6;BRD inhibitor ;https://doi.org/10.1038/s41586-020-2286-9;;;;
JQ1;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Lisinopril;;;inactive;;;Vero E6;ACE inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Lisinopril;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Loratadine;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Loratadine;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Histamine 1 receptor antagonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
Lovastatin;;;weak/inconclusive;;;Vero E6;HMG-CoA reductase inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Luminespib;;;U-shaped response;;;Vero E6;HSP90B1;https://doi.org/10.1038/s41586-020-2286-9;;;;
Merimepodib;;;;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Merimepodib;;;inconclusive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;IMPDH inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Metformin;;;inactive/inconclusive;;;Vero E6;MRC 1 inhibitor (indirect);https://doi.org/10.1038/s41586-020-2286-9;;;;
Metformin;;;retest at higher dose;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Midostaurin;;;agonist;;;Vero E6;Multi-targeted protein kinase inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Midostaurin;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Minoxidil;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;PLOD inhibitor ;https://doi.org/10.1038/s41586-020-2286-9;;;;
ML240;;;inactive;;;Vero E6;p97 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
ML240;;;active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Mycophenolic acid;;;;;;Vero E6;IMPDH inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Mycophenolic acid;;;active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
MZ1;;;active;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
MZ1;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Degrades BRD proteins;https://doi.org/10.1038/s41586-020-2286-9;;;;
Nafamostat;;;inactive;;;Vero E6;Serine protease 1 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Nafamostat;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Nitazoxanide;;;parital/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Olanzapine;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Onalespib;;;parital inhibition;;;Vero E6;HSP90B1;https://doi.org/10.1038/s41586-020-2286-9;;;;
Pazopanib;;;inactive;;;Vero E6;Type-1 kinase inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Pazopanib;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
PB28;;;active;;;Vero E6;Sigma 1/2 modulator;https://doi.org/10.1038/s41586-020-2286-9;;;;
PB28;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
PD-144418;;;weak activity/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
PD-144418;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma 1 antagonist ;https://doi.org/10.1038/s41586-020-2286-9;;;;
Pepstatin;;;inactive;;;Vero E6;protease inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
PF-846;;;weak/inconclusive;;;Vero E6;Ribosomal inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
PF-846;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Pimozide;;;inactive/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Pioglitazone;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ponatinib;;;;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ponatinib;;;active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;RIPK1 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Progesterone;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma1 antagonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
;;;;;;;Sigma2 binder;;;;;
PS3061;;;active;;;Vero E6;Sec61 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
PS3061;;;Inconclusive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Quercetin;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
RapaLink-1;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Rapamycin (Sirolimus);;;weak/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Rapamycin (Sirolimus);;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;mTOR inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ribavirin;;;inactive;;;Vero E6;IMPDH inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ribavirin;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Rimcazole;;;inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
RP101 (Brivudine);;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
RP101 (Brivudine);;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
RS-PPCC;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
RS-PPCC;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma 1 agonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ruxolitinib;;;agonist/inconclusive;;;Vero E6;Multi-targeted protein kinase inhibitor ;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ruxolitinib;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
RVX-208;;;inactive;;;Vero E6;BRD2/4 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
RVX-208;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Sapanisertib (INK128/MlN128);;;weak/inconclusive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Sapanisertib (INK128/MlN128);;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;mTOR inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Silmitasertib (CX-4945);;;active;;;Vero E6;CK2 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Siramesine;;;Active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Sigma1 agonist;https://doi.org/10.1038/s41586-020-2286-9;;;;
;;;;;;;Sigma2 agonist;;;;;
S-verapamil;;;;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
S-verapamil;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;Calcium channel, drug efflux transporter inhibitior;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ternatin 4 (DA3);;;active;;;Vero E6;eEF1A inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Ternatin 4 (DA3);;;Active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Tomivosertib (eFT-508);;;inactive;;;Vero E6;MNK1/2 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Tomivosertib (eFT-508);;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Valproic Acid;;;inactive;;;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
Valproic Acid;;;Inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;HDAC2 inhibitor ;https://doi.org/10.1038/s41586-020-2286-9;;;;
XL413;;;inactive;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;CDC7 inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Zotatifin (eFT226);;;active;;;Vero E6;EIF4a inhibitor;https://doi.org/10.1038/s41586-020-2286-9;;;;
Zotatifin (eFT226);;;Active;;SARS-CoV-2, isolate France/IDF0372/2020;Vero E6;;https://doi.org/10.1038/s41586-020-2286-9;;;;
N3;;16,77;;133;;Vero 6;inhibit multiple CoV Mpros;https://doi.org/10.1038/s41586-020-2223-y;;;;
Ebselem;;4,67;;;;Vero 6;;https://doi.org/10.1038/s41586-020-2223-y;;;;
Cinanserin;;20,61;;>200;;Vero 6;;https://doi.org/10.1038/s41586-020-2223-y;;;;
Abemaciclib  ;;6,62;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Abemaciclib  ;;43,7;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Amodiaquine dihydrochloride 5.15 ;;5,15;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Amodiaquine dihydrochloride 5.15 ;;>50;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Anidulafungin;;4,64;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Anidulafungin;;17,23;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Bazedoxifene ;;3,44;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Bazedoxifene ;;12,63;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Berbamine hydrochloride  ;;7,87;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Berbamine hydrochloride  ;;>50;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Cepharanthine  ;;4,47;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Cepharanthine  ;;30;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Chloroquine ;;7,28;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Chloroquine ;;69,2;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Ciclesonide ;;4,33;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Ciclesonide ;;10,6;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Cyclosporine  ;;5,82;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Cyclosporine  ;;4,69;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Digitoxin  ;;0,23;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Digitoxin  ;;0,16;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Digoxin ;;0,19;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Digoxin ;;0,72;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Eltrombopag ;;8,27;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Eltrombopag ;;8,38;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Gilteritinib  ;;6,76;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Gilteritinib  ;;>50;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Hexachlorophene  ;;0,9;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Hexachlorophene  ;;1,48;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Hydroxyprogesterone caproate;;6,3;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Hydroxyprogesterone caproate;;3,87;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Ivacaftor ;;6,57;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Ivacaftor ;;11,55;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Loperamide hydrochloride ;;9,27;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Loperamide hydrochloride ;;12,53;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Lopinavir ;;9,12;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Lopinavir ;;21,7;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Mefloquine ;;4,33;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Mefloquine ;; >50;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Nafamostat mesylate ;;0,0022;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Nafamostat mesylate ;;13,88;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Niclosamide  ;;0,28;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Niclosamide  ;;0,84;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Ouabain ;;<0.1 ;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Ouabain ;;<0.1;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Oxyclozanide ;;3,71;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Oxyclozanide ;;6,78;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Proscillaridin;;2,04;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Proscillaridin;;5,95;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Remdesivir ;;1,3;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Remdesivir ;;11,41;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Salinomycin sodium ;;0,24;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Salinomycin sodium ;;0,5;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3; ;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Tetrandrine ;;3;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Vero;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
Tetrandrine ;;13,5;;;SARS-CoV-2 (βCoV/KOR/KCDC03/2020);Calu-3;;https://doi.org/10.1101/2020.05.12.090035 ;;;;
cycloheximide;;0,17;;>0.5;patient isolate;Caco-2;inhibit translation elongation;https://doi.org/10.1038/s41586-020-2332-7;;;;
emetine;;0,47;;>1;patient isolate;Caco-2;inhibits 40S ribosomal protein S14;https://doi.org/10.1038/s41586-020-2332-7;;;;
pladienolide B;;0,0013;;0,007;patient isolate;Caco-2;spliceosome inhibitor targeting splicing factor SF3B1;https://doi.org/10.1038/s41586-020-2332-7;;;;
2-deoxy-D-glucose;;0,41;;9,09;patient isolate;Caco-2;inhibitor of hexokinase, glycolysis;https://doi.org/10.1038/s41586-020-2332-7;;;;
NMS-873;;0,025;toxic effect?;0,025;patient isolate;Caco-2;small molecule inhibitor of the AAA ATPase p97;https://doi.org/10.1038/s41586-020-2332-7;;;;
 Ribavirin;;0,07;toxic effect?;0,07;patient isolate;Caco-2;inhibition of nucleotide synthesi;https://doi.org/10.1038/s41586-020-2332-7;;;;
the pandemic response box ;400cpds;; sixteen compounds that showed inhibition of the SARS-CoV-2 after the survival screen;;SARS-CoV-2 (SARS-85 CoV-2/München-1.1/2020/929;Vero-E6;;https://doi.org/10.1101/2020.05.17.100404;;;;
Retro-2.1 ;;0,4909;;50;SARS-CoV-2 (SARS-85 CoV-2/München-1.1/2020/929;Vero-E6;Retrograde transport inhibitor  ;https://doi.org/10.1101/2020.05.17.100404;;;;
Chloroquine;;1,03;;50;SARS-CoV-2 (SARS-85 CoV-2/München-1.1/2020/929;Vero-E6;Autophagic proteolysis inhibitor ;https://doi.org/10.1101/2020.05.17.100404;;;;
N-Nonyl  Deoxyno  Jirimycin   (NNDNJ);;1,677;;50;SARS-CoV-2 (SARS-85 CoV-2/München-1.1/2020/929;Vero-E6;ER α-glucosidase inhibitors ;https://doi.org/10.1101/2020.05.17.100404;;;;
URMC-099-C;;0,335;;13,1;SARS-CoV-2 (SARS-85 CoV-2/München-1.1/2020/929;Vero-E6;Mixed-lineage kinase 3 inhibitor;https://doi.org/10.1101/2020.05.17.100404;;;;
Remdesivir;;1,842;;50;SARS-CoV-2 (SARS-85 CoV-2/München-1.1/2020/929;Vero-E6;Nucleoside analogue;https://doi.org/10.1101/2020.05.17.100404;;;;
Favipiravir ;T-705;207,1;;> 500;SARS-CoV-2 strain BavPat1;Vero-E6;nucleotide analogue;https://doi.org/10.1101/2020.05.15.098731;;;;
Miglustat;"Zavesca; N-butyl-1-deoxynojirimycin, NB-DNJ";41±22;;> 1000;SARS-CoV-2 strain ICGEB-FVG_5;Vero-E6;inhibits α-24 glucosidases I and II;https://doi.org/10.1101/2020.05.18.101691;;;;
oseltamivir carboxylic acid;;>100;inactive;;SARS-CoV-2;Vero-E6;neuraminidase inhibitor;https://doi.org/10.1101/2020.05.15.20102392;;;;
GZ-161;;~2;;;SARS-CoV-2 (GISAID accession EPI_ISL_406862);Vero-E6;inhibitor of  glucosylceramide synthase (GCS); https://doi.org/10.1101/2020.05.18.103283;;;;
GZ-346;;~2;;;SARS-CoV-2 (GISAID accession EPI_ISL_406862);Vero-E6;inhibitor of  glucosylceramide synthase (GCS); https://doi.org/10.1101/2020.05.18.103283;;;;
Gemcitabine;;1,24;active;>40;SARS-CoV-2 (WIV04);Vero-E6;inhibition of viral replication;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
lycorine;;0,31;active;>40;SARS-CoV-2 (WIV04);Vero-E6;inhibition of viral replication;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
oxysophoridine;;0,18;active;>40;SARS-CoV-2 (WIV04);Vero-E6;inhibition of viral replication;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
Chloroquine;;1,36;active;>40;SARS-CoV-2 (WIV04);Vero-E6;;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
Gemcitabine;;n.d.;active;;SARS-CoV-2 (WIV04);Huh-7;inhibition of viral replication;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
lycorine;;n.d.;active;;SARS-CoV-2 (WIV04);Huh-7;inhibition of viral replication;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
oxysophoridine;;n.d.;active;;SARS-CoV-2 (WIV04);Huh-7;inhibition of viral replication;https://doi.org/10.1080/22221751.2020.1772676 ;;;;
ROC-325;;3,28;;>30;SARS-CoV-2;Vero-E6;inhibit lysosome fusion;https://doi.org/10.1101/2020.05.16.091520;;;;
Clomipramine;;13,6;;>30;SARS-CoV-2;Vero-E6;inhibit autophagic flux;https://doi.org/10.1101/2020.05.16.091520;;;;
Hycanthone;;5,79;;14;SARS-CoV-2;Vero-E6;increase lysosomal membrane permeabilization ;https://doi.org/10.1101/2020.05.16.091520;;;;
Verteporfin;;inactive;inactive;>30;SARS-CoV-2;Vero-E6;inhibiting autophagic flux;https://doi.org/10.1101/2020.05.16.091520;;;;
Chloroquine;;2,01;;>30;SARS-CoV-2;Vero-E6;inhibit lysosome fusion;https://doi.org/10.1101/2020.05.16.091520;;;;
hydroxychloroquine;;4,47;;>30;SARS-CoV-2;Vero-E6;inhibit lysosome fusion;https://doi.org/10.1101/2020.05.16.091520;;;;
Mefloquine;;3,85;;8,78;SARS-CoV-2;Vero-E6;autophagic flux;https://doi.org/10.1101/2020.05.16.091520;;;;
remdesivir ;;7,04;;;SARS-CoV-2;Vero-E6;;https://doi.org/10.1101/2020.05.16.091520;;;;
CbAE-1;;0,7344;;653,1;pseudo SARS-CoV-2;HEK-293T-ACE2;secreted bacterial lipase; https://doi.org/10.1101/2020.05.22.109900;;;;
CbAE-1;;2,991;;653,1;SARS-CoV-2;Vero;secreted bacterial lipase; https://doi.org/10.1101/2020.05.22.109900;;;;
CbAE-2;;1,041;;>1000;pseudo SARS-CoV-2;HEK-293T-ACE2;secreted bacterial lipase; https://doi.org/10.1101/2020.05.22.109900;;;;
CbAE-2;;2,49;;>1000;SARS-CoV-2;Vero;secreted bacterial lipase; https://doi.org/10.1101/2020.05.22.109900;;;;
Simeprevir;;4,082;;19,33;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;protease inhibitor ; https://doi.org/10.1101/2020.05.26.116020;;;;
Redesivir;;4,269;;>200;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;nucleoside analogue ;https://doi.org/10.1101/2020.05.26.116020;#NAME?;;;
Bromocriptine Mesylate;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Bictegravir;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Entecavir;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
 Zidovudine;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Sofosbuvir;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Atovaquone;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Daclatasvir;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Saquinavir;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
Asunaprevir;;>10;;;SARS-CoV-2  (BetaCoV/Hong Kong/VM20001061/2020, SCoV2);Vero-E6;;https://doi.org/10.1101/2020.05.26.116020;;;;
chloroquine diphosphate, racemic ;;1,801;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
chloroquine diphosphate, R-;;1,975;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
chloroquine diphosphate, S-;;1,761;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
hydroxychloroquine sulfate, racemic;;1,752;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
hydroxychloroquine sulfate, R-;;2,445;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
hydroxychloroquine sulfate, S-;;1,444;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
azithromycin;;~10;;;SARS-CoV-2 (Genebank accession no. MT123290.1);Vero-E6;;https://doi.org/10.1101/2020.05.26.114033;;;;
Amiodarone;;0,052;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Bosutinib;;0,02;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Clofazamine;;0,084;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Gilteritinib  ;;0,224;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Verapamil;;0,533;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Thioguanine;;0,216;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Z-FA-FMK;;0,107;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Metociopramide;;0,468;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
S1RA;;0,222;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Entecavir;;0,042;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Remdesivir;;0,006;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Niclosamide  ;;0,142;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Fedratinib;;0,024;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Lomitapide;;0,766;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Lactoferrin;;0,308;;>1;SARS-CoV-2 WA1;Huh-7;;https://doi.org/10.1101/2020.05.27.117184;;;;
Interferon-β1A;IFN-β1a;0.76 IU/ml;;;SARS-CoV-2 (USA-WA1/2020);Vero;;https://www.ncbi.nlm.nih.gov/pubmed/32360182;;;;
Interferon-ɑ;IFN-α;1.35 IU/ml ;;;SARS-CoV-2 (USA-WA1/2020);Vero;;https://www.ncbi.nlm.nih.gov/pubmed/32360182;;;;
Remdesivir;;0,826;;>20;SARS-CoV-2;VeroE6;;https://doi.org/10.21203/rs.3.rs-30934/v1;;;;
Hydroxychloroquine;;0,733;;>20;SARS-CoV-2;VeroE6;;https://doi.org/10.21203/rs.3.rs-30934/v1;;;;
Famotidine;;>100;;>100;SARS-CoV-2;VeroE6;;https://doi.org/10.21203/rs.3.rs-30934/v1;;;;
Ivermectin;;2.2 - 2.8;;;SARS-CoV-2 (Australia/VIC01/2020);Vero/hSLAM;binds to and destabilises the Impα/β1 heterodimer;https://www.ncbi.nlm.nih.gov/pubmed/32251768;;;;
Remdesivir;;0,38;;>100 ;SARS-CoV-2 patient derived;Caco-2;; https://doi.org/10.1016/j.ijid.2020.05.085;;;;
Darunavir;;>100;not active;>100 ;SARS-CoV-2 patient derived;Caco-2;; https://doi.org/10.1016/j.ijid.2020.05.085;;;;
